132139-15-2

Basic information

• Product Name: (S)-N,N-diphenyl-2-pyrrolidinecarboxamide
• Synonyms: (S)-N,N-diphenyl-2-pyrrolidinecarboxamide
• CAS NO: 132139-15-2
• Molecular Weight: 266.343
• Mol File: 132139-15-2.mol

Chemical Properties

• CAS DataBase Reference: (S)-N,N-diphenyl-2-pyrrolidinecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-N,N-diphenyl-2-pyrrolidinecarboxamide(132139-15-2)
• EPA Substance Registry System: (S)-N,N-diphenyl-2-pyrrolidinecarboxamide(132139-15-2)

Safety Data

• Hazardous Substances Data: 132139-15-2(Hazardous Substances Data)

Upstream product

• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 61350-60-5 (S)-benzyloxycarbonyl-proline acid chloride 
• 62-53-3 aniline 
• 220510-58-7 tert-butyl (S)-2-(phenylcarbamoyl)pyrrolidine-1-carboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 319-61-9 (S)-1-(trifluoroacetyl)pyrrolidine-2-carboxylic acid 
• 36724-68-2 (S)-N-trifluoroacetylproline acid chloride 
• 223769-31-1 (S)-1-(2,2,2-Trifluoro-acetyl)-pyrrolidine-2-carboxylic acid diphenylamide 

Downstream Products

• 223769-30-0 (S)-N,N-diphenyl-2-pyrrolidinemethanamine 

Relevant articles and documents

CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS

Provided and set forth herein are certain cyclized acetamido derivatives that are DNA Polymerase Theta (Ροlθ) inhibitors of Formula (I) and Formula (II). Also, provided are pharmaceutical compositions comprising such compounds, and methods of treating diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers, using such compounds and pharmaceutical compositions.

Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity

Signal transducer and activator of transcription 6 (STAT6) transmits signals from cytokines IL-4 and IL-13 and is activated in allergic airway disease. We are developing phosphopeptide mimetics targeting the SH2 domain of STAT6 to block recruitment to phosphotyrosine residues on IL-4 or IL-13 receptors and subsequent Tyr641 phosphorylation to inhibit the expression of genes contributing to asthma. Structure-affinity relationship studies showed that phosphopeptides based on Tyr631 from IL-4Rα bind with weak affinity to STAT6, whereas replacing the pY+3 residue with simple aryl and alkyl amides resulted in affinities in the mid to low nM range. A set of phosphatase-stable, cell-permeable prodrug analogues inhibited cytokine-stimulated STAT6 phosphorylation in both Beas-2B human airway cells and primary mouse T-lymphocytes at concentrations as low as 100 nM. IL-13-stimulated expression of CCL26 (eotaxin-3) was inhibited in a dose-dependent manner, demonstrating that targeting the SH2 domain blocks both phosphorylation and transcriptional activity of STAT6.

Enantioselective synthesis of binaphthol derivatives by oxidative coupling of naphthol derivatives catalyzed by chiral diamine-copper complexes

A highly efficient process of aerobic oxidative coupling of 2-naphthol derivatives catalyzed by 1 mol % of Cu(OH)Cl·TMEDA has been developed. Enantioselective oxidative coupling of naphthols was achieved by the use of 10 mol % of chiral catalysts prepared from proline-derived diamines and cuprous chloride, affording the corresponding binaphthols in good enantioselectivities of up to 78% ee. The ester moiety at the 3-position of the substrate was found to be essential for the good asymmetric induction observed in the present coupling reaction.